ST
MACK

Spot Trading’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Spot Trading’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-2,405
Closed -$122K – 5019
2014
Q1 		$95K Buy
+2,405
New +$103K ﹤0.01% 3459

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
TA
Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return
LIM
Lagoda Investment Management New York $162M AUM 49.7% 1-Year Est. Return

Spot Trading's MACK Position: Q2 2014 in Review

Spot Trading sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2014, closing a stake of 2,405 shares — an estimated $122K sold.

Spot Trading first reported a position in MACK in Q1 2014 and held it in 1 quarter. The position peaked at $95K in Q1 2014. 121 funds tracked by Wall St. Rank hold MACK as of Q2 2014.

  • Spot Trading reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2014 after selling out during the quarter.
  • Spot Trading sold 2,405 Merrimack Pharmaceuticals, Inc. shares in Q2 2014, an estimated $122K.
  • Spot Trading first reported a position in Merrimack Pharmaceuticals, Inc. in Q1 2014 and held it in 1 quarter.
  • Spot Trading's Merrimack Pharmaceuticals, Inc. position peaked at $95K in Q1 2014.
  • 121 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2014.

Based on Spot Trading's 13F filing for Q2 2014, filed 12 Aug 2014.